🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

951 results for “Eli” Clear

  1. VGX-3100

    INOVIO PHARMACEUTICALS, INC.

    Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)

    phase 2 mab completed

    1 trial

  2. Valemetostat Tosylate, Valemetostat Tosylate

    The George Institute

    Adult patients with histologically/cytologically confirmed progressive metastatic or recurrent solid tumor, who have selected chromatin remodeling deficiency in at least one of the following genes: SMARCB1, SMARCA4, SMARCA2, SMARCC1, SMARCC2, ARID1A, ARID1B, PBRM1, BAP1and other SWI/SNF sub-units; or molecularly (Wildtype) and phenotypically-selected Clear cell endometrial or ovarian carcinoma cancers.

    phase 2 small molecule active

    1 trial

  3. Vedolizumab

    Takeda

    Celiac Disease

    phase 2 small molecule terminated

    1 trial

  4. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  5. Verzenios 50 mg film-coated tablets, TEMOZOLOMIDE , IRINOTECAN , Abemaciclib, Abemaciclib

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial

  6. Vixarelimab

    Kiniksa Pharmaceuticals International, plc

    Prurigo Nodularis

    phase 2 small molecule completed

    1 trial

  7. WIDUS computer-delivered, indirect brief intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Drug Abuse

    phase 2 other completed

    1 trial

  8. Yondelis 1 mg powder for concentrate for solution for infusion, DOXORUBICINE ARROW 2 mg/ml, solution pour perfusion

    Ningbo Cancer Hospital

    Localized, resected, FIGO stage I (2018 classification), uterine leiomyosarcoma

    phase 2 small molecule active

    1 trial

  9. ZED1227 + SIGE

    Takeda

    Celiac Disease

    phase 2 small molecule active

    1 trial

  10. ZIMBERELIMAB

    Arcus Biosciences

    Pancreatic Cancer

    phase 2 small molecule on hold

    1 trial

  11. Zimberelimab

    Arcus Biosciences

    Adenocarcinoma Stomach

    phase 2 small molecule terminated

    1 trial

  12. Zimberelimab

    Arcus Biosciences

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  13. Zimberelimab

    Arcus Biosciences

    Melanoma

    phase 2 small molecule active

    1 trial

  14. Zimberelimab

    Arcus Biosciences

    Hepatobiliary Cancer

    phase 2 small molecule active

    1 trial

  15. Zimberelimab (ZIM)

    Arcus Biosciences

    Lung Cancer

    phase 2 small molecule active

    1 trial

  16. Zimberelimab, Trodelvy 200 mg powder for concentrate for solution for infusion

    Fondazione Telethon ETS

    Muscle-Invasive Bladder cancer

    phase 2 small molecule active

    1 trial

  17. Zirconium Zr 89 Girentuximab

    Telix Innovations

    Clear Cell Renal Cell Carcinoma

    phase 2 small molecule active

    1 trial

  18. [68Ga]BED003 injection

    Blue Earth Diagnostics Ireland Ltd

    Colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).

    phase 2 small molecule active

    1 trial

  19. anagrelide hydrochloride

    Takeda

    Essential Thrombocythaemia

    phase 2 small molecule completed

    1 trial

  20. cetrelimab, JNJ-63723283

    Janssen-Cilag International N.V.

    Advanced Stage Solid Tumors

    phase 2 small molecule active

    1 trial

  21. chidamide + camrelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  22. combination with Disitamab Vedotin and with Tislelizumab and Capecitabine

    Hospital Authority, Hong Kong

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  23. disitamab vedotin

    Pfizer

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  24. entinostat

    Syndax Pharmaceuticals

    Epithelial Ovarian Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources